XML 41 R24.htm IDEA: XBRL DOCUMENT

Financial instruments

6 Months Ended

11 Months Ended

Jun. 30, 2020

Dec. 31, 2019

The Group’s financial instruments consist primarily of cash and cash equivalents, accounts receivables, accounts payable and contingent considerations. We believe that the recorded values of cash and cash equivalents, accounts receivables, accounts payable approximate their current fair values because of their nature and respective maturity dates or durations. The fair value of our contingent consideration liability is determined based on “Level 3” inputs.


Fair Value Measurement as of June 30, 2020
	Level 1				Level 2			Level 3		Total
Liabilities
Contingent consideration	$	—	$	—		$	—	$	—
Total	$	—	$	—		$	—	$	—
Fair Value Measurement as of December 31, 2019
	Level 1				Level 2			Level 3		Total
Liabilities
Contingent consideration	$	—	$	—		$	105	$	105
Total	$	—	$	—		$	105	$	105

The contingent consideration relates to the acquisition of Discuva Limited in December 2017 based on the terms of the share purchase agreement. The Group reassessed the contingent consideration in line with the anticipated settlement of consideration liability during the three months ended June 30, 2020 and determined no further payments were required under the agreement. The remaining balance of $0.1 million was reversed to the consolidated statement of operations and other comprehensive loss.

Financial instruments


Fair Value Measurement as of December 31, 2019
	Level 1		Level 2		Level 3		Total
Liabilities
Contingent consideration	$	—	$	—	$	105	$	105
Total	$	—	$	—	$	105	$	105
Fair Value Measurement as of January 31, 2019
	Level 1		Level 2		Level 3		Total
Liabilities
Contingent consideration	$	—	$	—	$	825	$	825
Total	$	—	$	—	$	825	$	825

The contingent consideration relates to the acquisition of Discuva Limited in December 2017 based on the terms of the share purchase agreement. During the eleven-months ended December 31, 2019 and years ended January 31, 2019 and 2018,

payments of $0.7 million, $0.3 million and $0 were made during the same periods and the Group reassessed the contingent consideration in line with the anticipated settlement of consideration liability.

The fair value of the contingent consideration is measured using the discounted cashflow forecast model. The expected payments are primarily due to research and development tax credits received and receivable by Discuva in respect to financial years prior to the Group's acquisition, of which the sellers are due a specified portion of these amounts.

The following table is a reconciliation of our Level 3 liabilities recorded at fair value using significant unobservable inputs:


In thousands
Balance January 31, 2018	$	—
Acquisition	1,099
Payment	(243)

Foreign currency translation	(31)
Balance January 31, 2019	825
Payments	(699)
Foreign currency translation	(21)
Balance December 31, 2019	$	105

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details